Surya Singh, MD, discussed dynamics that affect biosimilar uptake on the medical benefits side and how that differs from the pharmacy benefits side at the recent FDA/Federal Trade Commission workshop on anticompetitive practices.
Surya Singh, MD, is the president of Singh Healthcare Advisors
Transcript:
What are some of the dynamics that affect biosimilar uptake on the medical benefits side versus the pharmacy benefits side?
On the pharmacy benefit side, just to start there, the formulary concept and preferred drug concepts are critical to user uptake. So, getting that contract to become the preferred product, which in today's market is really around achieving the lowest net cost, is really critical. And that's done on a really large scale through a few entities, [which] do a lot of the procurement on the pharmacy benefit side; whereas, on the medical benefits side, individual health systems, academic medical centers, for instance, and then large multidisciplinary practices or specialty specific practices do their own procurement. So, the splintering of the market is much greater, and providers have to think about what would be the best, really, largely from an economic perspective, so [what would be the] lowest cost for them to inventory and then use across all of their patients and be able to [bill] for and receive reimbursement for across all of their patients. If it's a pure play, and it's going through either benefit, then the adoption issues become more clear, given that kind of framework. What becomes even more complicated is when there's both pharmacy benefit coverage and adjudication and medical benefit coverage and adjudication. So, you have both to contend with.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.